CELYAD
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
CELYAD
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2007-01-01
Address:
Mont-saint-guibert, Brabant Wallon, Belgium
Country:
Belgium
Website Url:
http://www.celyad.com
Total Employee:
51+
Status:
Active
Contact:
+32(0) 10 39 41 00
Email Addresses:
[email protected]
Total Funding:
146.1 M USD
Technology used in webpage:
Person Schema Gravatar Profiles Lorem Ipsum Comcast 3 To 9 CcTLD Redirects
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-06-30 | Biological Manufacturing Services | Biological Manufacturing Services acquired by Celyad | N/A |
| 2015-01-06 | OnCyte | OnCyte acquired by Celyad | N/A |
| 2014-11-05 | CorQuest Medical | CorQuest Medical acquired by Celyad | N/A |
Investors List
Fortress Investment Group
Fortress Investment Group investment in Post-IPO Equity - Celyad
Hunza Ventures
Hunza Ventures investment in Venture Round - Celyad
Grifols
Grifols investment in Venture Round - Celyad
Life Sciences Research Partners V.Z.W.
Life Sciences Research Partners V.Z.W. investment in Series B - Celyad
Hunza Ventures
Hunza Ventures investment in Series B - Celyad
Grifols
Grifols investment in Series B - Celyad
S.R.I.W.
S.R.I.W. investment in Series A - Celyad
Official Site Inspections
http://www.celyad.com Semrush global rank: 3.57 M Semrush visits lastest month: 4.05 K
- Host name: 109.230.214.35.bc.googleusercontent.com
- IP address: 35.214.230.109
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Celyad"
Celyad - Crunchbase Company Profile & Funding
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno …See details»
Celyad Oncology Announces Strategic Review - Business Wire
Jun 24, 2025 MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext: CYAD) (the “Company”), today announces two poster presentations at …See details»
Celyad Oncology (EBR:CYAD) Company Profile & Description
1 day ago Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates …See details»
Celyad SA - AnnualReports.com
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company …See details»
Celyad Oncology Announces Strategic Review - Euronext Live
Jun 24, 2025 Celyad reiterated this process is exploratory, and no final determinations have been made. About Celyad Oncology. Celyad Oncology is a cutting-edge biotechnology …See details»
Celyad - businessabc
Feb 25, 2025 Celyad was founded in 2007 and has its co-headquarters in Mont-Saint-Guibert and New York. The company provides innovative therapeutics to patients suffering from …See details»
About Us - Celyad
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the …See details»
Celyad Company Profile - Office Locations, Competitors, Revenue …
Celyad has 5 employees across 2 locations and €186 k in annual revenue in FY 2024. See insights on Celyad including office locations, competitors, revenue, financials, executives, …See details»
Celyad Company Profile | Management and Employees List
Celyad is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, with additional operations in New York. The company …See details»
Celyad Oncology Announces €1 Million Private Placement
2 days ago Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard …See details»
Celyad Oncology Announces €1 Million Private Placement
1 day ago MONT-SAINT-GUIBERT, Belgium, July 28, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") today announced that it has entered into a …See details»
Celyad Rebrands as Celyad Oncology | The Belgium Journal
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company …See details»
2024 ANNUAL REPORT - celyad.com
Organization and values..... 62 2.8.3. Risks analysis..... 63. 2024 Annual Report 2 2.8.4. Risks related to the Company’s financial position, capital requirements and governance ... Today, …See details»
Celyad Oncology Announces Intent to Voluntarily Delist American ...
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on …See details»
Celyad Oncology Announces €1 Million Private Placement
2 days ago Celyad Oncology is a cutting-edge biotechnology company focused primarily on unlocking the potential of its proprietary CAR-T technology platforms and intellectual property. …See details»
Newsroom - Celyad
Celyad Oncology reports full year 2024 financial results and recent business highlights. Download PDF. 18. Feb 2025. non-regulated information, Press Releases. Celyad Oncology announces …See details»
Celyad Oncology Announces Strategic Review - Yahoo Finance
Jun 24, 2025 Matt Kane, Chief Executive Officer of Celyad, commented: "The Board is now exploring multiple strategic alternatives.Potential options include forming collaborations or co …See details»
Celyad Oncology reports full year 2022 financial results and recent ...
Mar 23, 2023 This impairment comes as a result of the Company’s strategic shift in focus away from clinical development and the early stage nature of the implementation of the Celyad 2.0 …See details»
2021 ANNUAL REPORT - Celyad
Including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of …See details»
Celyad Oncology provides an update on its strategic business …
Dec 21, 2022 MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on …See details»